ArticleGastro hep advances2026
Sex-Specific Differences in Outcomes and Trends in Patients With Ulcerative Colitis.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Sex-based differences in immune-mediated diseases are becoming more widely recognized, but there is very limited research exploring sex-based differences in ulcerative colitis (UC), particularly more severe forms of UC. Some recent studies have suggested lower colectomy rates in female patients with UC. The objective of this study is to assess the association between sex and outcomes of patients with UC, particularly those with more severe forms of the disease requiring hospitalization. Methods: A propensity score matched retrospective cohort study was performed using TriNetX, a multi-institutional database, to compare risk of colectomy, hospitalization, and mortality between male and female patients with UC, including subgroup analyses of those who had been hospitalized, had received intravenous steroids within 2 weeks of hospitalization or had received infliximab within 1 month of hospitalization. Results: Males had a statistically significant increased risk of colectomy (odds ratio (OR) 1.50, 95% confidence interval (CI) 1.40-1.61; OR 1.47, 95% CI 1.38-1.57), hospitalization (OR 1.04, 95% CI 1.02-1.06; OR 1.02, 95% CI 1.00-1.04), and mortality (OR 1.28, 95% CI 1.21-1.34; OR 1.32, 95% CI 1.28-1.37) at 1 year and at 5 years after diagnosis. Similar results were found when focusing on hospitalized UC patients and males receiving intravenous steroids within 2 weeks of hospitalization. For patients receiving infliximab within 1 month of hospitalization only colectomy rates were significantly different between males and females at the 1-year timepoint. Conclusion: Male patients with UC are at higher risk for colectomy, hospitalization, and mortality than females with UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.